New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
08:02 EDTEGRXEagle Pharmaceuticals says FDA acceptsa NDA for Ryanodex
Eagle Pharmaceuticals announced that the United States Food and Drug Administration has accepted the company’s New Drug Application for Ryanodex and granted a priority review classification. The PDUFA date is July 22. In January 2014, Eagle filed its NDA with the FDA for the treatment of malignant hyperthermia. In February 2014, the FDA conditionally accepted Eagle’s trade name Ryanodex. Ryanodex has previously been granted Orphan Drug designation and Eagle currently owns three U.S. patents covering the product. Eagle intends to commercialize Ryanodex after approval and will retain exclusive marketing rights in the U.S.
News For EGRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
07:32 EDTEGRXEagle Pharmaceuticals price target raised to $51 from $37 at Cantor
Cantor increased its price target on Eagle (EGRX) after the FDA found that Teva's (TEVA) liquid Treanda drug is incompatible with various commonly used polycarbonate-containing injection devices, while the Treanda that Eagle licensed to Teva does not have this problem. The firm thinks this discrepancy will create a number of benefits for Eagle, and it reiterates a Buy rating on the stock.
March 25, 2015
07:00 EDTEGRXEagle Pharmaceuticals management to meet with Piper Jaffray
Subscribe for More Information
March 18, 2015
10:08 EDTEGRXEagle Pharmaceuticals price target increased to $67 from $43 at William Blair
William Blair raised its price target on Eagle Pharmaceuticals to $67 from $43 citing its belief that the company can become profitable and have significant cash flow pending the approval of EP-3102. The company added that it view last week's FDA label change for Teva's (TEVA) Treanda as a positive for EP-3102 and that its new price target assumes 2016 launch and "reasonable" penetration for EP-3102.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use